| アイテムタイプ |
学術雑誌掲載論文(1) |
| 公開日 |
2025-10-08 |
| タイトル |
|
|
タイトル |
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302 |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 著者 |
Hara Hiroki
Satoh Taroh
Kojima Takashi
Tsushima Takahiro
Sunakawa Yu
Okada Morihito
Ding Ningning
Wu Hongqian
Li Liyun
Yu Tian
Barnes Gisoo
Kato Ken
|
| キーワード |
|
|
言語 |
en |
|
主題 |
Esophageal squamous cell carcinoma, Japan, Programmed cell death protein 1 inhibitor, Tislelizumab |
| 識別子 |
|
|
識別子 |
https://doi.org/10.1007/s10388-023-01040-w |
|
識別子タイプ |
DOI |
| 書誌情報 |
en : Esophagus : official journal of the Japan Esophageal Society
巻 21,
号 2,
p. 102-110,
ページ数 9,
発行日 2024-01-19
|
| 出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1612-9067 |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 権利情報 |
|
|
権利情報 |
© The Author(s) 2024 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
s10388-023-01040-w.pdf (585 KB)
.png)
